20 citations
,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
September 2020 in “Journal of Health, Medicine and Nursing” A 10-year-old boy with abnormal genital development had surgery and tests to find the cause and plan treatment.
November 2024 in “Scientific Reports” Chemotherapy for male germ cell tumors often leads to hypogonadism and related symptoms.
1 citations
,
April 2012 in “Urology” Self-management can help improve symptoms of benign prostatic hyperplasia.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).
109 citations
,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
23 citations
,
May 1984 in “Journal of the American Geriatrics Society” Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
April 2018 in “The Journal of urology/The journal of urology” A new score can help predict which patients might have trouble urinating after prostate surgery.
October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
86 citations
,
March 1993 in “Toxicology and Applied Pharmacology” Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.
March 2026 in “Canadian Urological Association Journal” The commentary by Udi Blankstein highlights the growing gap between wellness marketing claims and scientific evidence in men's health, particularly in urology. Many therapies, such as IV nutrient therapy and cold water immersion, are heavily marketed for benefits like testosterone optimization and fertility, yet lack supporting evidence. Conversely, low-level laser therapy for androgenetic alopecia is one area where evidence supports marketing claims, showing improvements in hair density. The review by Qaoud et al emphasizes the need for urologists to provide nuanced counseling, acknowledging where evidence exists and where it does not, as men increasingly seek proactive health measures based on commercially driven information.
January 2016 in “Renal Failure” Kidney stones and hair loss are significantly related in people under 60 years old.
48 citations
,
January 2005 in “Treatments in Endocrinology” 
November 2014 in “Elsevier eBooks” Gene mutations can cause problems in male genital development.
April 2013 in “The Journal of Urology” Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
1 citations
,
July 2016 in “Reactions Weekly” Finasteride can cause itching, burning, and other side effects that may not go away after treatment.
18 citations
,
June 2016 in “PeerJ” Testosterone increases certain kidney protein levels, potentially raising blood pressure.
March 2013 in “The Journal of Urology” Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
7 citations
,
September 1997 in “PubMed” December 2008 in “The Journal of Urology” 
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
1 citations
,
October 2024 in “JCEM Case Reports” 5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Thorough evaluation is crucial for postmenopausal women with virilization to detect rare ovarian tumors.
1 citations
,
April 2019 in “The Journal of urology/The journal of urology” Marijuana use is linked to higher chances of needing treatment for urinary symptoms in men over 40.
June 2022 in “Research Square (Research Square)” Urinary stones increased in Wuwei, China, especially in males, suggesting the need for better screening and healthcare.
March 2008 in “European Urology Supplements” Finasteride and dutasteride can affect sexual function in BPH patients.
November 2022 in “American Journal of Clinical Pathology” TURP specimens should be checked for various tumors, not just common prostate issues.